News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Intercell AG Sees U.S. JE Vaccine Approval in Early 2009
December 29, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
VIENNA, Dec 29 (Reuters) - Austrian biotech firm Intercell (ICEL.VI) said on Monday it expects U.S. approval for its Japanese Encephalitis (JE) vaccine to move into early 2009, later than expected.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Asia
Europe
MORE ON THIS TOPIC
Insights
The Italian inflection point: Clinical strength, culture and capital
August 13, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Rare diseases
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
August 12, 2026
·
3 min read
·
Annalee Armstrong
FDA
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
August 12, 2026
·
1 min read
·
Jef Akst
Manufacturing
FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
August 11, 2026
·
1 min read
·
Gabrielle Masson
